WuXi STA: China approves first CMO-made new drug

By Flora Southey contact

- Last updated on GMT

(Image: Getty/artorn)
(Image: Getty/artorn)
The first candidate made in accordance with China’s Marketing Authorisation Holder pilot programme has received new drug application approval.

The China Food and Drug Administration (CFDA) has approved Ascletis’ new drug application (NDA) for viral hepatitis C treatment Ganovo.

Made by contract development and manufacturing organisation (CDMO) WuXi STA​ – a subsidiary of WuXi AppTec​ – Ganovo is the first ‘new drug’ to receive regulatory approval in China since the country adopted its Marketing Authorisation Holder (MAH) pilot programme.

The MAH programme​ refers to China’s changing contract manufacturing organisation (CMO) policies. As of May 2016, China’s State Council has opened the market to GMP-compliant third party manufactures in some provinces to make pharmaceutical drug products for customers.

Anti-viral agent Ganovo – also known as Danoprevir or ASC08 – is the product of a five-year collaboration between Ascletis and WuXi STA.   

According to the CDMO, WuXi STA “supported the process optimisation and process validation of Ganovo active pharmaceutical ingredient (API) as well as Ganovo’s NDA submission and approval.”

The active pharmaceutical ingredient (API) was manufactured at WuXi STA’s Jinshan site, and Ganovo is only approved in China, we were told.

In a statement​ released earlier today, WuXi STA CEO Minzhang Chen said: “The strong support received from the Chinese government for new drugs and the successful implementation of ‘MAH’ pilot was integral to reaching this milestone.”

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Related suppliers

Follow us


View more